411 related articles for article (PubMed ID: 33172883)
1. Immunogenic cell death pathway polymorphisms for predicting oxaliplatin efficacy in metastatic colorectal cancer.
Arai H; Xiao Y; Loupakis F; Kawanishi N; Wang J; Battaglin F; Soni S; Zhang W; Mancao C; Salhia B; Mumenthaler SM; Weisenberger DJ; Liang G; Cremolini C; Falcone A; Millstein J; Lenz HJ
J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33172883
[TBL] [Abstract][Full Text] [Related]
2. aCGH Analysis of Predictive Biomarkers for Response to Bevacizumab plus Oxaliplatin- or Irinotecan-Based Chemotherapy in Patients with Metastatic Colorectal Cancer.
Fujita Y; Taguri M; Yamazaki K; Tsurutani J; Sakai K; Tsushima T; Nagase M; Tamagawa H; Ueda S; Tamura T; Tsuji Y; Murata K; Taira K; Denda T; Moriwaki T; Funai S; Nakajima TE; Muro K; Tsuji A; Yoshida M; Suyama K; Kurimoto T; Sugimoto N; Baba E; Seki N; Sato M; Shimura T; Boku N; Hyodo I; Yamanaka T; Nishio K
Oncologist; 2019 Mar; 24(3):327-337. PubMed ID: 30425180
[TBL] [Abstract][Full Text] [Related]
3. Clinical significance of enterocyte-specific gene polymorphisms as candidate markers of oxaliplatin-based treatment for metastatic colorectal cancer.
Suenaga M; Schirripa M; Cao S; Zhang W; Cremolini C; Lonardi S; Okazaki S; Berger MD; Miyamoto Y; Soni S; Barzi A; Yamaguchi T; Loupakis F; Falcone A; Lenz HJ
Pharmacogenomics J; 2021 Jun; 21(3):285-295. PubMed ID: 33542444
[TBL] [Abstract][Full Text] [Related]
4. Clinical Validation of a Machine-learning-derived Signature Predictive of Outcomes from First-line Oxaliplatin-based Chemotherapy in Advanced Colorectal Cancer.
Abraham JP; Magee D; Cremolini C; Antoniotti C; Halbert DD; Xiu J; Stafford P; Berry DA; Oberley MJ; Shields AF; Marshall JL; Salem ME; Falcone A; Grothey A; Hall MJ; Venook AP; Lenz HJ; Helmstetter A; Korn WM; Spetzler DB
Clin Cancer Res; 2021 Feb; 27(4):1174-1183. PubMed ID: 33293373
[TBL] [Abstract][Full Text] [Related]
5. Prognostic Effect of Adenosine-related Genetic Variants in Metastatic Colorectal Cancer Treated With Bevacizumab-based Chemotherapy.
Tokunaga R; Cao S; Naseem M; Lo JH; Battaglin F; Puccini A; Berger MD; Soni S; Millstein J; Zhang W; Stintzing S; Loupakis F; Cremolini C; Heinemann V; Falcone A; Lenz HJ
Clin Colorectal Cancer; 2019 Mar; 18(1):e8-e19. PubMed ID: 30293873
[TBL] [Abstract][Full Text] [Related]
6. Germ line polymorphisms of genes involved in pluripotency transcription factors predict efficacy of cetuximab in metastatic colorectal cancer.
Arai H; Millstein J; Loupakis F; Stintzing S; Wang J; Battaglin F; Kawanishi N; Jayachandran P; Soni S; Zhang W; Mumenthaler SM; Cremolini C; Heinemann V; Falcone A; Lenz HJ
Eur J Cancer; 2021 Jun; 150():133-142. PubMed ID: 33901792
[TBL] [Abstract][Full Text] [Related]
7. Phase II Randomized Trial of Sequential or Concurrent FOLFOXIRI-Bevacizumab Versus FOLFOX-Bevacizumab for Metastatic Colorectal Cancer (STEAM).
Hurwitz HI; Tan BR; Reeves JA; Xiong H; Somer B; Lenz HJ; Hochster HS; Scappaticci F; Palma JF; Price R; Lee JJ; Nicholas A; Sommer N; Bendell J
Oncologist; 2019 Jul; 24(7):921-932. PubMed ID: 30552157
[TBL] [Abstract][Full Text] [Related]
8. AMPK variant, a candidate of novel predictor for chemotherapy in metastatic colorectal cancer: A meta-analysis using TRIBE, MAVERICC and FIRE3.
Tokunaga R; Cao S; Naseem M; Battaglin F; Lo JH; Arai H; Loupakis F; Stintzing S; Puccini A; Berger MD; Soni S; Zhang W; Mancao C; Salhia B; Mumenthaler SM; Weisenberger DJ; Liang G; Cremolini C; Heinemann V; Falcone A; Millstein J; Lenz HJ
Int J Cancer; 2019 Oct; 145(8):2082-2090. PubMed ID: 30856283
[TBL] [Abstract][Full Text] [Related]
9. Potential role of PIN1 genotypes in predicting benefit from oxaliplatin-based and irinotecan-based treatment in patients with metastatic colorectal cancer.
Suenaga M; Schirripa M; Cao S; Zhang W; Yang D; Cremolini C; Lonardi S; Bergamo F; Ning Y; Yamamoto N; Okazaki S; Berger MD; Miyamoto Y; Gopez R; Barzi A; Yamaguchi T; Stintzing S; Heinemann V; Loupakis F; Falcone A; Lenz HJ
Pharmacogenomics J; 2018 Sep; 18(5):623-632. PubMed ID: 29925895
[TBL] [Abstract][Full Text] [Related]
10. TWIST1 Polymorphisms Predict Survival in Patients with Metastatic Colorectal Cancer Receiving First-Line Bevacizumab plus Oxaliplatin-Based Chemotherapy.
Matsusaka S; Zhang W; Cao S; Hanna DL; Sunakawa Y; Sebio A; Ueno M; Yang D; Ning Y; Parekh A; Okazaki S; Berger MD; Ichikawa W; Mizunuma N; Lenz HJ
Mol Cancer Ther; 2016 Jun; 15(6):1405-11. PubMed ID: 26983880
[TBL] [Abstract][Full Text] [Related]
11. Randomized Phase II Trial of CapOX plus Bevacizumab and CapIRI plus Bevacizumab as First-Line Treatment for Japanese Patients with Metastatic Colorectal Cancer (CCOG-1201 Study).
Nakayama G; Mitsuma A; Sunagawa Y; Ishigure K; Yokoyama H; Matsui T; Nakayama H; Nakata K; Ishiyama A; Asada T; Umeda S; Ezaka K; Hattori N; Takami H; Kobayashi D; Tanaka C; Kanda M; Yamada S; Koike M; Fujiwara M; Fujii T; Murotani K; Ando Y; Kodera Y
Oncologist; 2018 Aug; 23(8):919-927. PubMed ID: 30049885
[TBL] [Abstract][Full Text] [Related]
12. Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial.
Cremolini C; Antoniotti C; Rossini D; Lonardi S; Loupakis F; Pietrantonio F; Bordonaro R; Latiano TP; Tamburini E; Santini D; Passardi A; Marmorino F; Grande R; Aprile G; Zaniboni A; Murgioni S; Granetto C; Buonadonna A; Moretto R; Corallo S; Cordio S; Antonuzzo L; Tomasello G; Masi G; Ronzoni M; Di Donato S; Carlomagno C; Clavarezza M; Ritorto G; Mambrini A; Roselli M; Cupini S; Mammoliti S; Fenocchio E; Corgna E; Zagonel V; Fontanini G; Ugolini C; Boni L; Falcone A;
Lancet Oncol; 2020 Apr; 21(4):497-507. PubMed ID: 32164906
[TBL] [Abstract][Full Text] [Related]
13. Impact of genetic variants involved in the lipid metabolism pathway on progression free survival in patients receiving bevacizumab-based chemotherapy in metastatic colorectal cancer: a retrospective analysis of FIRE-3 and MAVERICC trials.
Wang J; Millstein J; Yang Y; Stintzing S; Arai H; Battaglin F; Kawanishi N; Soni S; Zhang W; Mancao C; Cremolini C; Liu T; Heinemann V; Falcone A; Shen L; Lenz HJ
EClinicalMedicine; 2023 Mar; 57():101827. PubMed ID: 36816347
[TBL] [Abstract][Full Text] [Related]
14. Clinical Significance of TLR1 I602S Polymorphism for Patients with Metastatic Colorectal Cancer Treated with FOLFIRI plus Bevacizumab.
Okazaki S; Loupakis F; Stintzing S; Cao S; Zhang W; Yang D; Ning Y; Sunakawa Y; Stremitzer S; Matsusaka S; Berger MD; Parekh A; West JD; Miyamoto Y; Suenaga M; Schirripa M; Cremolini C; Falcone A; Heinemann V; DePaolo RW; Lenz HJ
Mol Cancer Ther; 2016 Jul; 15(7):1740-5. PubMed ID: 27196764
[TBL] [Abstract][Full Text] [Related]
15. Single Nucleotide Polymorphisms in MiRNA Binding Sites of Nucleotide Excision Repair-Related Genes Predict Clinical Benefit of Oxaliplatin in FOLFOXIRI Plus Bevacizumab: Analysis of the TRIBE Trial.
Suenaga M; Schirripa M; Cao S; Zhang W; Yang D; Cremolini C; Murgioni S; Lonardi S; Ning Y; Okazaki S; Berger MD; Miyamoto Y; Barzi A; Loupakis F; Falcone A; Lenz HJ
Cancers (Basel); 2020 Jun; 12(7):. PubMed ID: 32629861
[TBL] [Abstract][Full Text] [Related]
16. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study.
Cremolini C; Loupakis F; Antoniotti C; Lupi C; Sensi E; Lonardi S; Mezi S; Tomasello G; Ronzoni M; Zaniboni A; Tonini G; Carlomagno C; Allegrini G; Chiara S; D'Amico M; Granetto C; Cazzaniga M; Boni L; Fontanini G; Falcone A
Lancet Oncol; 2015 Oct; 16(13):1306-15. PubMed ID: 26338525
[TBL] [Abstract][Full Text] [Related]
17. Predictive value of TLR7 polymorphism for cetuximab-based chemotherapy in patients with metastatic colorectal cancer.
Okazaki S; Stintzing S; Sunakawa Y; Cao S; Zhang W; Yang D; Ning Y; Matsusaka S; Berger MD; Miyamoto Y; Suenaga M; Schirripa M; West JD; Gopez R; Akihito T; Ichikawa W; Heinemann V; DePaolo RW; Lenz HJ
Int J Cancer; 2017 Sep; 141(6):1222-1230. PubMed ID: 28569041
[TBL] [Abstract][Full Text] [Related]
18. A Polymorphism within the Vitamin D Transporter Gene Predicts Outcome in Metastatic Colorectal Cancer Patients Treated with FOLFIRI/Bevacizumab or FOLFIRI/Cetuximab.
Berger MD; Stintzing S; Heinemann V; Cao S; Yang D; Sunakawa Y; Matsusaka S; Ning Y; Okazaki S; Miyamoto Y; Suenaga M; Schirripa M; Hanna DL; Soni S; Puccini A; Zhang W; Cremolini C; Falcone A; Loupakis F; Lenz HJ
Clin Cancer Res; 2018 Feb; 24(4):784-793. PubMed ID: 29208668
[No Abstract] [Full Text] [Related]
19. [KRAS mutation does not influence oxaliplatin or irinotecan efficacy, in association with bevacizumab, in first line treatment of metastatic colorectal cancer].
Cabart M; Frénel JS; Campion L; Ramée JF; Dupuis O; Senellart H; Hiret S; Douillard JY; Bennouna J
Bull Cancer; 2016 Jun; 103(6):541-51. PubMed ID: 27155924
[TBL] [Abstract][Full Text] [Related]
20. Prognostic Value of ACVRL1 Expression in Metastatic Colorectal Cancer Patients Receiving First-line Chemotherapy With Bevacizumab: Results From the Triplet Plus Bevacizumab (TRIBE) Study.
Hanna DL; Loupakis F; Yang D; Cremolini C; Schirripa M; Li M; Matsusaka S; Berger MD; Miyamoto Y; Zhang W; Ning Y; Antoniotti C; Salvatore L; Moran M; Zeger G; Astrow SH; Falcone A; Lenz HJ
Clin Colorectal Cancer; 2018 Sep; 17(3):e471-e488. PubMed ID: 29636300
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]